Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31134314 | 1.00 | GRM5 (0.53) | GRM5ACACBPIK3CAMTORHAO1 | |
| SCHEMBL22066488 | 0.82 | ACACB (0.49) | GRM5ACACB | |
| SCHEMBL17761625 | 0.81 | GRM5 (0.55) | GRM5ACACBPIK3CAMTORHAO1 | |
| SCHEMBL22031558 | 0.79 | GRM5 (0.54) | GRM5ACACBPIK3CAMTORHAO1 | |
| SCHEMBL6821195 | 0.78 | GRM5 (0.56) | GRM5ACACBPIK3CAMTORHAO1 | |
| SCHEMBL27960959 | 0.77 | ACACB (0.40) | ACACBHAO1NNMT | |
| SCHEMBL30977145 | 0.77 | GABRA1 (0.34) | GRM5CYP2A6 | |
| SCHEMBL2516789 | 0.77 | GABRA1 (0.34) | GRM5CYP2A6 | |
| SCHEMBL6817623 | 0.76 | GRM5 (0.55) | GRM5ACACBPIK3CAMTORHAO1 | |
| SCHEMBL28420312 | 0.76 | GRM5 (0.51) | GRM5ACACBPIK3CAMTORHAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113620945-A | RET inhibitor, pharmaceutical composition thereof and application thereof in medicines | 广东东阳光药业有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | CAPRARO HANS-GEORG | 2007-09-13 | — | — | US | disclosed |
| EP-1689747-A1 | 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054238-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| WO-2004016605-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AS ADENOSINE A1 AND A2A RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | ABL1, PRKCA, PRKCQ | GRM5 2160/4885ACACB 1590/4885PIK3CA 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.